MedTrace Logo

The Purpose of This Study is to Evaluate the Efficacy and Safety of 627 in the Treatment of UC

NCT07507513 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 288

Last updated 2026-04-02

No results posted yet for this study

Summary

This study will evaluate the efficacy and safety of 627 in patients with UC.

Conditions

  • Ulcerative Colitis (UC)

Interventions

DRUG

627

627 subcutaneous (SC) injection.

DRUG

Placebo

Placebo subcutaneous (SC) injection.

Sponsors & Collaborators

  • Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-31
Primary Completion
2029-02-28
Completion
2029-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07507513 on ClinicalTrials.gov